BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, Kawamori R, Yamasaki Y. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol. 1998;28:189-193. [PMID: 9514530 DOI: 10.1016/0168-8278(88)80004-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Deshpande P, Bundell C, McKinnon E, Hellard M, Ffrench R, Wilkinson AL, Drummer H, Gaudieri S, Lucas M. Frequent occurrence of low-level positive autoantibodies in chronic hepatitis C. Pathology 2020;52:576-83. [PMID: 32580891 DOI: 10.1016/j.pathol.2020.05.001] [Reference Citation Analysis]
2 Lim TR, Hazlehurst JM, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA, Tomlinson JW. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol (Oxf). 2019;90:440-448. [PMID: 30586166 DOI: 10.1111/cen.13924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
3 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
4 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
5 Hardikar W, Schwarz KB. Treatment options for chronic hepatitis B and C infection in children. Expert Review of Anti-infective Therapy 2014;4:583-91. [DOI: 10.1586/14787210.4.4.583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Milner KL, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, Xu A, George J, Chisholm DJ. Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. J Viral Hepat. 2014;21:325-332. [PMID: 24716635 DOI: 10.1111/jvh.12143] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
7 Eslam M, Aparcero R, Mousa YI, Grande L, Shaker Y, Ali A, Del Campo JA, Khattab MA, Romero-Gomez M. Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. J Clin Gastroenterol. 2012;46:228-234. [PMID: 22298085 DOI: 10.1097/mcg.0b013e31822a2dc6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
8 Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094. [PMID: 22399695 DOI: 10.2337/dc11-1837] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
9 Huang JF, Yu ML, Huang CF, Juo SH, Dai CY, Hsieh MY, Hou NJ, Yeh ML, Hsieh MH, Yang JF. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int. 2012;32:962-969. [PMID: 22356575 DOI: 10.1111/j.1478-3231.2012.02771.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
10 Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7. [PMID: 20234345 DOI: 10.1038/ajg.2010.110] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
11 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance. Gut Liver. 2009;3:108-115. [PMID: 20431732 DOI: 10.5009/gnl.2009.3.2.108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
12 Forrester JE, McGovern BH, Rhee MS, Sterling RK. The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population. HIV Med 2009;10:555-63. [PMID: 19496835 DOI: 10.1111/j.1468-1293.2009.00722.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
13 Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res. 2009;2009:483485. [PMID: 19132131 DOI: 10.1155/2009/483485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
14 Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2009;24:42-48. [PMID: 18717762 DOI: 10.1111/j.1440-1746.2008.05503.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
15 Overbeck K, Genné D, Golay A, Negro F; Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008;49:295-8. [PMID: 18555553 DOI: 10.1016/j.jhep.2008.03.033] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
16 Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract 2007;13:126-30. [PMID: 17490925 DOI: 10.4158/EP.13.2.126] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
17 Regev A, Schiff ER. Viral hepatitis. Curr Opin Gastroenterol 1999;15:234-9. [PMID: 17023950 DOI: 10.1097/00001574-199905000-00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075-7080. [PMID: 17131467 DOI: 10.1111/j.1478-3231.2010.02365.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
19 Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-6. [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 12.3] [Reference Citation Analysis]
20 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
21 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12(44): 7075-7080 [PMID: 17131467 DOI: 10.3748/wjg.v12.i44.7075] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 103] [Article Influence: 7.0] [Reference Citation Analysis]
22 Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications. 2006;20:113-120. [PMID: 16504840 DOI: 10.1016/j.jdiacomp.2006.01.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
23 Hwang SJ, Chen LK. Chronic hepatitis C and diabetes mellitus. J Chin Med Assoc 2006;69:143-5. [PMID: 16689193 DOI: 10.1016/S1726-4901(09)70194-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lu J, Chuang L, Yang W, Tai T, Lai M, Chen P, Kao J, Lee C, Lee H. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005;25:752-9. [DOI: 10.1111/j.1478-3231.2005.1007.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ertekin V, Selimoğlu MA, Orbak Z. Effects of lamivudine therapy on the glucose metabolism in children with chronic hepatitis B: first year follow-up results. Eur J Gastroenterol Hepatol 2005;17:655-9. [PMID: 15879728 DOI: 10.1097/00042737-200506000-00010] [Reference Citation Analysis]
26 Romero-gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-de-rueda P, López-serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41. [DOI: 10.1053/j.gastro.2004.12.049] [Cited by in Crossref: 536] [Cited by in F6Publishing: 492] [Article Influence: 31.5] [Reference Citation Analysis]
27 Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005;100:48-55. [PMID: 15654780 DOI: 10.1111/j.1572-0241.2005.40429.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 5.7] [Reference Citation Analysis]
28 Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233. [PMID: 15183143 DOI: 10.1016/j.clim.2004.01.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 3.9] [Reference Citation Analysis]
29 Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58. [PMID: 12969081 DOI: 10.1046/j.1365-2036.2003.01681.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
30 Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002;32:43-50. [PMID: 11851726 DOI: 10.1046/j.0014-2972.2001.00940.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
31 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
32 Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest. 2000;30:111-121. [PMID: 10651835 DOI: 10.1046/j.1365-2362.2000.00608.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.0] [Reference Citation Analysis]
33 Vial T, Choquet-kastylevsky G, Liautard C, Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 2000;142:161-72. [DOI: 10.1016/s0300-483x(99)00141-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
34 Imano E, Kanda T, Nakatani Y, Motomura M, Arai K, Matsuhisa M, Yamasaki Y, Hori M. Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. J Hepatol. 1999;31:469-473. [PMID: 10488706 DOI: 10.1016/s0168-8278(99)80039-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
35 Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol. 1999;31:215-220. [PMID: 10453932 DOI: 10.1016/S0168-8278(99)80216-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
36 Khanna S, Roy S, Packer L, Sen CK. Cytokine-induced glucose uptake in skeletal muscle: redox regulation and the role of alpha-lipoic acid. Am J Physiol 1999;276:R1327-33. [PMID: 10233023 DOI: 10.1152/ajpregu.1999.276.5.R1327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.2] [Reference Citation Analysis]